Coherus BioSciences Inc. (CHRS)
1.00
-0.00 (-0.50%)
At close: Mar 04, 2025, 9:52 AM
Coherus BioSciences Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | 257.24M | 211.04M | 326.55M | 475.82M | 356.07M | 1.56M | 1.56M | 190.11M | 30.04M | 31.11M | 2.75M | 1.9M |
| Cost of Revenue | 162.78M | 70.08M | 57.59M | 37.67M | 17.08M | 3.23M | 160.53M | 254.44M | 212.68M | 78.22M | 31.28M | 34.89M |
| Gross Profit | 94.46M | 140.96M | 268.96M | 438.16M | 338.99M | -1.68M | -158.97M | -64.33M | -182.64M | -47.12M | -28.53M | -32.99M |
| Operating Income | -203.2M | -256.88M | -263.86M | 156.32M | 107.77M | -204.42M | -232.14M | -115.93M | -219.07M | -64.68M | -35.99M | -38.52M |
| Interest Income | n/a | 30.57M | 21.56M | 20.57M | 16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -238.27M | -291.75M | -287.1M | 135.71M | 92.78M | -209.41M | -238.29M | -127.79M | -223.94M | -87.18M | -53.63M | -33.02M |
| Net Income | -237.89M | -326.63M | -306.32M | 132.24M | 89.83M | -209.34M | -238.17M | -127.34M | -223.26M | -87.13M | -53.63M | -33.02M |
| Selling & General & Admin | 185.62M | 198.48M | 169.71M | 139.08M | 137.04M | 94.18M | 71.3M | 51.6M | 36.05M | 17.56M | 7.46M | 5.53M |
| Research & Development | 109.44M | 199.36M | 363.11M | 142.76M | 94.19M | 110.24M | 162.39M | 254.44M | 213.06M | 78.22M | 31.28M | 34.89M |
| Other Expenses | n/a | 3.82M | -283K | 554K | 2.61M | 4.69M | 3.4M | -3.88M | -4.84M | -18.59M | -12.35M | 7.01M |
| Operating Expenses | 301.45M | 397.84M | 532.82M | 281.84M | 231.22M | 204.42M | 233.69M | 306.04M | 249.11M | 95.79M | 38.74M | 40.42M |
| Interest Expense | 40.54M | 32.47M | 22.96M | 21.17M | 17.6M | 9.68M | 9.55M | 7.98M | 33K | 3.9M | 5.29M | 1.51M |
| Selling & Marketing Expenses | n/a | 10.5M | 8.7M | 3.8M | 4.5M | 2.8M | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 460.44M | 467.92M | 590.41M | 319.5M | 248.3M | 204.42M | 233.69M | 306.04M | 249.11M | 95.79M | 38.74M | 40.42M |
| Income Tax | -380K | 34.87M | 19.22M | 3.46M | 2.94M | 4.69M | 9.44M | 656K | -7.35M | -15.41M | -7.06M | 8.53M |
| Shares Outstanding (Basic) | 94.16M | 77.63M | 75.45M | 71.41M | 69.68M | 65.01M | 53.13M | 41.91M | 37.12M | 8.19M | 18.08M | 18.08M |
| Shares Outstanding (Diluted) | 94.16M | 77.63M | 75.45M | 83.49M | 73.19M | 65.03M | 53.13M | 41.91M | 37.12M | 8.19M | 18.08M | 18.08M |
| EPS (Basic) | -2.53 | -4.21 | -4.06 | 1.85 | 1.29 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -2.97 | -1.83 |
| EPS (Diluted) | -2.53 | -4.21 | -4.06 | 1.62 | 1.23 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -2.97 | -1.83 |
| EBITDA | -193.94M | -255.58M | -260.69M | 161.84M | 111.03M | -204.42M | -225.34M | -116.81M | -222.04M | -82.72M | -47.94M | -31.28M |
| Depreciation & Amortization | 3.79M | 3.7M | 5.66M | 4.97M | 3.26M | 3.23M | 3.4M | 3M | 1.87M | 674K | 404K | 221K |